Denali Therapeutics Inc (DNLI) - Kapitalizatsiyaning foydaga nisbati
Denali Therapeutics (DNLI) gumanitar maqom himoyasi ostida G'arb yetakchilari bilan hamkorlik qilib, dori vositalarini miyaga yetkazib berishning noyob usulini ishlab chiqmoqda. Emitentning P/E koeffitsiyenti investitsiyalarning qoplanish muddatini ko'rsatadi, -9.60 ko'rsatkichi esa joriy baholash holatini belgilaydi. Biroq, Osiyo yetkazib beruvchilariga bog'liqlik va eksport cheklovlari dasturiy ta'minotning global klinik sinovlarini sekinlashtirishi mumkin.
denalitherapeutics.com (DNLI) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- bozor kapitallashuvi ko'rsatkichlari:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning xususiy kapitalga nisbati Denali Therapeutics|DNLI - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga koeffitsiyenti Denali Therapeutics Inc.|DNLI - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Denali Corp|DNLI - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli majburiyatlar miqdori Denali Therapeutics|Oraliq qoplash koeffitsiyenti denalitherapeutics.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
DNLI - Sof foyda|Kutilayotgan sof foyda Denali Therapeutics|DNLI - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori Denali Therapeutics Inc|DNLI - PEG multiplikatori|EV/EBITDA multiplikatori Denali Therapeutics Inc|DNLI - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi 12 oy davomida bitta aksiya uchun foyda Denali Therapeutics|DNLI - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi denalitherapeutics.com|DNLI - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Denali Therapeutics
- kompaniyaning sotuvlari va tushumi statistikasi:
Kompaniyaning umumiy tahlili:Denali Therapeutics Inc - DNLI
Denali Therapeutics (DNLI) innovatsion miya dori vositalarini yetkazib berish usullarini ishlab chiqish orqali uzoq muddatli patent salohiyatini shakllantirmoqda, bu esa hozirda bozor tomonidan aksiyalar narxiga kiritilmoqda. Kompaniyaning joriy P/E koeffitsiyentini tahlil qilish orqali investorlar bozor kapitalizatsiyasi va haqiqiy daromadlar o'rtasidagi bog'liqlikni baholaydilar, bu esa kapitalga yuqori ehtiyoj seziladigan biotexnologiya sektoridagi kapital tannarxi va likvidlilik risklarini real vaqt rejimida baholash imkonini beradi.
Raqobatdosh kompaniyalar
Narxning foydaga nisbati BIIB|P/E multiplikatori NBIX|Regencell (RGC) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati axsome.com AXSM|P/E multiplikatori ACADIA Pharmaceuticals ACAD|XENE - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Narxning foydaga nisbati|CPRX (Catalyst Pharmaceuticals) - Narxning foydaga nisbati|Narxning foydaga nisbati Harmony Biosciences Holdings, Inc.|Narxning foydaga nisbati BHVN|Narx-foyda koeffitsiyenti AMLX (Amylyx Pharmaceuticals, Inc.)|Bozor narxining sof foydaga nisbati TRVI|Narxning foydaga nisbati Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Narxning foydaga nisbati|CBLL: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati PRTA (prothena.com)|Alector, Inc. (ALEC) - Narxning foydaga nisbati|Narx-foyda multiplikatori ANNX|Narxning foydaga nisbati Omeros Corp.|Neurogene Therapeutics (NGNE) - Biznesning o‘zini qoplash muddati|P/E multiplikatori ACIU|VYGR (Voyager Therapeutics) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori NMRA (neumoratx.com)|SCLX: Narx-foyda multiplikatori|TVGN - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Alpha Cognition Inc.|CGTX: P/E multiplikatori|inhibikase.com (IKT) - P/E multiplikatori|Narxning foydaga nisbati Cassava Sciences Inc|ASRT - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati Coya (COYA)|P/E multiplikatori VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E multiplikatori|Biznesning o‘zini qoplash muddati alteritytherapeutics.com ATHE|CLNN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati PepGen Corp (PEPG)|Narxning foydaga nisbati Jupiter Neurosciences, Inc.|RLMD: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ANVS|Narx-foyda koeffitsiyenti Grace Tx GRCE|Narxning foydaga nisbati Firefly Neuroscience, Inc AIFF|KLTO: Narx-foyda multiplikatori|NRSN - Narxning foydaga nisbati|RVPH: Narxning foydaga nisbati|MTVA (MetaVia Inc.) - Narx-foyda koeffitsiyenti|NeurAxis Inc. (NRXS) - P/E multiplikatori|Narxning foydaga nisbati Helius Medical|Passage Bio, Inc. - Kapitalizatsiyaning sof foydaga nisbati|Narx-foyda koeffitsiyenti NEUP (Neuphoria)|NERV - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ATHA (athira.com)|P/E multiplikatori Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E multiplikatori|CYCN - P/E multiplikatori|PTIX (Protagenic Therapeutics, Inc.) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati Pasithea (KTTA)|Narxning foydaga nisbati Cortigent|Kapitalizatsiyaning foydaga nisbati Avenue Therapeutics Inc. ATXI|Narxning foydaga nisbati brainstorm-cell.com (BCLI)|Narx-foyda koeffitsiyenti Cara Therapeutics, Inc CARA|P/E multiplikatori CHRO (chromocell.com)|Kompaniya qiymatining sof foydaga nisbati ELYM|Intra-Cellular Therapies Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Longboard Pharmaceuticals Inc|Marinus (MRNS) - Narxning foydaga nisbati|NKGN - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati NeuroBo Pharmaceuticals|SAGE: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SNPX|Trevena Inc. - Narx-foyda multiplikatori|Narxning foydaga nisbati Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Narxning foydaga nisbati|Cerevel Therapeutics - P/E multiplikatori
